Shortened Therapy for Hepatitis C Virus Genotype 2 or 3 — Is Less More?
2007; Massachusetts Medical Society; Volume: 357; Issue: 2 Linguagem: Inglês
10.1056/nejme078092
ISSN1533-4406
Autores Tópico(s)Monoclonal and Polyclonal Antibodies Research
ResumoInfection with hepatitis C virus (HCV) is a major worldwide cause of chronic liver disease, cirrhosis, and liver cancer, which together represent a chief global public health burden. Therapy has improved substantially since the introduction of interferon-alfa monotherapy in the late 1980s, when the response rate was less than 10%; now, combination therapy with peginterferon and ribavirin has a success rate of about 50%.1,2 Much like the diverse outcomes of HCV infection, the response to treatment varies. Important factors associated with treatment response include the race, age, sex, weight, and biochemical and histologic characteristics of patients. However, viral genotype . . .
Referência(s)